Recently, Australia’s Therapeutic Goods Administration (TGA) approved lenacapavir for use as pre-exposure prophylaxis (PrEP). This brings both exciting possibilities and important questions about access for people who want a pharmaceutical option to reduce their risk of contracting HIV.

We caught up with PAMS co-ordinator Sarah Lord to get the benefit of her years of experience in helping Victorians on OTP.

Tips from those who've done it.